We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




IVDR-Certified Mass Spectrometry Diagnostic System to Transform Detection of Monoclonal Gammopathies

By LabMedica International staff writers
Posted on 29 Aug 2023
Print article
Image: The IVDR-certified EXENT solution can transform diagnosis and monitoring of patients with monoclonal gammopathies (Photo courtesy of Thermo Fisher)
Image: The IVDR-certified EXENT solution can transform diagnosis and monitoring of patients with monoclonal gammopathies (Photo courtesy of Thermo Fisher)

Monoclonal gammopathies, including multiple myeloma, rank as the second most prevalent blood cancer globally, according to the 2020 report from the World Health Organization. Traditionally, treatment for these conditions involves monitoring M-protein levels, which can indicate the size of tumors. Despite significant treatment advancements, many patients are now achieving M-protein concentrations below detectable limits through standard methods. Yet, variations in disease progression persist within this patient group. Now, a new solution addresses this unmet clinical need for more sensitive analytical techniques that can differentiate between subsets of patients without resorting to invasive bone marrow biopsies prematurely.

Thermo Fisher Scientific (Waltham, MA, USA) has commercially launched the EXENT Solution after obtaining IVDR certification. This comprehensive and automated mass spectrometry system is designed to revolutionize diagnosis and assessment for individuals with monoclonal gammopathies. By utilizing the EXENT Solution, clinical laboratories can precisely measure, quantify, and monitor specific endogenous M-proteins and exogenous therapeutic monoclonal antibodies with heightened analytical sensitivity and precision in serum samples. The EXENT Solution has been developed to support the diagnosis of monoclonal gammopathies and facilitate the monitoring of patients with multiple myeloma and Waldenström's macroglobulinemia.

The EXENT Solution seamlessly integrates into routine laboratory workflows and comprises three integrated modules: EXENT-iP 500, an automated sample preparation instrument; EXENT-iX 500, a Matrix Assisted Laser Desorption Ionization - Time of Flight Mass Spectrometer (MALDI-ToF MS); and EXENT-iQ, an intelligent and user-friendly workflow software with data review capabilities. The system is complemented by the EXENT Immunoglobulin Isotypes (GAM) immunoassay, which is highly sensitive and specific for measuring and quantifying IgG, IgA, and IgM. The EXENT Solution is now available for commercial use in several countries, including Belgium, France, Germany, Italy, the Netherlands, Spain, and the United Kingdom.

“The EXENT Solution represents a significant breakthrough in innovation for the detection and monitoring of monoclonal immunoglobulins,” said Dr. Stephen Harding, Chief Scientific Officer, Protein Diagnostics, Thermo Fisher.

Related Links:
Thermo Fisher Scientific

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.